Our discoveries have been supported by European Institutions. Over the past years, our company has been recognized for our innovation with a variety of national and international awards.
2019-2023
EU Fast Track to Innovation
Clinical validation and production scale up of a novel product for healing of Pressure Ulcers, Leg Ulcers and Diabetic Foot Ulcers.
One of very few companies in the EU to receive SME phase 2 and FTI: Production scale and further clinical studies.
2019-2021
Eurostars Award
A novel bio-material is to dramatically decrease the cost of treatment of severe wounds and burns.
Awards for a 3D product for deep wounds, bioprinting and scaffolds.
2016-2017
EU Horizon 2020 SME Phase 2 Award
Novel Biomaterial for improved and cost-efficient wound healing
Success rate < 5%
Funding for both pre-clinical and clinical studies.
2015
EU Horizon 2020 SME phase 1 award
Novel Biomaterial for improved and cost-efficient wound healing
Success rate < 10%
Business model awarded for a novel wound healing product.
UK Wound Care Award
Biovotec Asked by NIHR WoundTec HTC To Present At The World Extreme Medicine Expo In London UK.
2014
Research Council of Norway
A new biomaterial available for wound healing
R&D program awarded for research with Institutes and Universities with funding for 4 years.
The Research Tax Credit (CIR) has been awarded to Biovotec to support its business research and development (R&D) activities.
Biovotec has been awarded the Young Innovative company status (JEI) which is only allocated to new companies investing in research and development (R&D)
